Log in to search using one of your social media accounts:

 

Mutational Profiles of Primary Myelofibrosis and Other MPNs Mutational Profiles of Primary Myelofibrosis and Other MPNs
This study analyzed the mutational profiles and cytogenetic abnormalities of three common chronic myeloproliferative neoplasms, with the aim of facilitating diagnosis between them.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms. (Source: CancerNetwork)
Source: CancerNetwork - July 15, 2017 Category: Cancer & Oncology Authors: Leslie Padrnos, MD Ruben A. Mesa, MD Tags: Hematologic Malignancies Oncology Journal Review Article Source Type: news

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms
Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

UT Health taps new leader for San Antonio cancer center
UT Health San Antonio has selected Dr. Ruben A. Mesa to serve as director of its UT Health Cancer Center. Mesa is currently professor of medicine and chair of the Division of Hematology& Medical Oncology at the Mayo Clinic in Arizona. He is also deputy director of the Mayo Clinic Cancer Center. UT Health San Antonio President Dr. William Henrich said Mesa is an international expert on myeloproliferative neoplasms, a group of bone marrow disorders that often lead to leukemia. Mesa has been a principal… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 13, 2017 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

UT Health taps new leader for San Antonio cancer center
UT Health San Antonio has selected Dr. Ruben A. Mesa to serve as director of its UT Health Cancer Center. Mesa is currently professor of medicine and chair of the Division of Hematology& Medical Oncology at the Mayo Clinic in Arizona. He is also deputy director of the Mayo Clinic Cancer Center. UT Health San Antonio President Dr. William Henrich said Mesa is an international expert on myeloproliferative neoplasms, a group of bone marrow disorders that often lead to leukemia. Mesa has been a principal… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 13, 2017 Category: Biotechnology Authors: W. Scott Bailey Source Type: news

Mayo Clinic PathWays: What's the diagnosis?
This week's case study reviews the bone marrow biopsy and myeloproliferative neoplasm ??malignant disease associated with increased production of blood cells ??workup from a 60-year-old woman who presented with two years of progressive transfusion-dependent anemia. Can you make the diagnosis? View the case and make your diagnosis. Learn more about Mayo Clinic PathWays. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2017 Category: Databases & Libraries Source Type: news

Overview of Myeloproliferative Disorders
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2017 Category: Cancer & Oncology Authors: Srdan Verstovsek, MD, PhD Tags: Hematologic Malignancies Conferences/ICHM 2017 News Source Type: news

Outlook for 2017: Myeloma, Lymphoma, and MPNs
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms. (Source: CancerNetwork)
Source: CancerNetwork - December 23, 2016 Category: Cancer & Oncology Authors: Amrita Y. Krishnan, MD David Snyder, MD Robert Chen, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news

Novel Germline Mutations in the Calreticulin Gene Novel Germline Mutations in the Calreticulin Gene
The authors identify germline mutations in the calreticulin gene which differ from those that define classic myeloproliferative neoplasms. What might their role be in the etiology of these disorders?Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Novartis today announced results from the first-ever international survey of patients with myeloproliferative neoplasms (MPNs), specifically myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET), which indicate that the majority of patients living with these MPNs experience a reduced quality of life. (Source: World Pharma News)
Source: World Pharma News - December 5, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Perinatal Transient Myeloproliferative Disorder in Trisomy 21
Transient myeloproliferative disorder (TMD), also known as transient acute myelopoiesis, is a myeloproliferative condition that occurs in the perinatal period in up to 10% of patients who have Down syndrome. Because of the perinatal presentation of this disorder, neonatal clinicians should be familiar with its clinical presentation, management, and outcomes. Affected patients develop severe myeloproliferation of megakaryocytic precursor cells, leading initially to hepatosplenomegaly and liver dysfunction. If the disorder develops prenatally, affected fetuses may also develop hydrops. The disorder requires the presence of 2...
Source: NeoReviews recent issues - October 31, 2016 Category: Pediatrics Authors: OConnell, A. E., Mulla, B. M., OBrien, K., Yoon, E. J., Carterson, A., Brodsky, D. Tags: Pediatric Drug Labeling Update Articles Source Type: news

Update on the Management of Myeloproliferative Neoplasms
In this interview we discuss symptoms and prognosis for patients with polycythemia vera and essential thrombocythemia and the treatment of myelofibrosis. (Source: CancerNetwork)
Source: CancerNetwork - September 30, 2016 Category: Cancer & Oncology Authors: Ruben A. Mesa, MD Tags: Hematologic Malignancies Conferences/NCCN 2016 Source Type: news

Learning units launched to mark leukaemia day
Nursing Times has today launched new online education resources on haematological cancers known as myeloproliferative neoplasms to coincide with International Chronic Myeloid Leukaemia Day. (Source: Nursing Times)
Source: Nursing Times - September 22, 2016 Category: Nursing Source Type: news

The 3rd Annual US Focus on Myeloproliferative Neoplasms and...
Expert review and analysis of the latest scientific advances in MPN and MDS(PRWeb August 16, 2016)Read the full story at http://www.prweb.com/releases/2016/08/prweb13615206.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2016 Category: Pharmaceuticals Source Type: news

Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news

Detection and Genotyping of CALR Mutations in Myeloproliferative NeoplasmsDetection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms
The authors developed a PCR-based approach to detect CALR mutations in myeloproliferative neoplasms, which can reduce labor and improve turnaround time in the clinical lab. American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 18, 2015 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Drug Active in Myeloproliferative Disorders (CME/CE)
(MedPage Today) -- Essential thrombocythemia, myelofibrosis respond to telomere targeting (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 2, 2015 Category: Hematology Source Type: news

MPN Research Foundation Encourages People to Use Social Media During...
During September as part of Blood Cancer Awareness Month, MPN Research Foundation asks people to raise awareness for myeloproliferative neoplasms by changing their Facebook profile picture(PRWeb August 28, 2015)Read the full story at http://www.prweb.com/releases/2015/08/prweb12926272.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2015 Category: Pharmaceuticals Source Type: news

AOP Orphan Pharmaceuticals announces progress of Phase III Trial PROUD-PV
Ropeginterferon alfa 2b is a novel, long-acting, mono-pegylated Interferon, administered only once every 14 days, after achieving therapy response even only monthly. Based on previous Phase I/II trials, Ropeginterferon alfa 2b is expected to be safe and effective in the majority of PV patients. Haematological and molecular responses occured in most patients; moreover, several patients achieved undetectable mutated JAK2 levels and a complete normalisation of their chromosomal make-up. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 10, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care JAK2 Latest News myeloproliferative neoplasms Polycythemia Vera PROUD-PV Ropeginterferon alfa 2b Source Type: news

Myelodysplastic Syndromes / Myeloproliferative Disorders
What are myelodysplastic syndromes?Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterized by ineffective hemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukemia in a third of patients. Who is affected?15% of cases occur after chemotherapy or radiotherapy for a previous cancer. The syndromes are most common in elderly people. What is the cause?The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages. What are the symptoms?Clinical manifestations result from cytopenias (anemia, infection, and b...
Source: Clinical Cases and Images - March 3, 2015 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Video Source Type: news

How Common is Gout?
Discussion Purines are heterocyclic aromatic organic compounds. Common ones are adenine, guanine, xanthine, hypoxanthine, uric acid and caffeine. The most common sources of purines are meat (especially liver, kidney, and brain), certain fish (herring, mackerel, anchovies, sardines), and in lower amounts in beans, and certain plants and yeast. Purines are synthesized, used by the body, then they are degraded by a variety of enzymes. They then can be salvaged to resynthesize purines or are eliminated primarily by the kidney. When intake or synthesis outweighs elimination then hyperuricemia can result. Hyperuricemia can occu...
Source: PediatricEducation.org - February 16, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

MPN Research Foundation initiates exploratory gene editing project
CRISPR technology to be evaluated for its applicability and safety for blood cancer group myeloproliferative neoplasms.(PRWeb February 12, 2015)Read the full story at http://www.prweb.com/releases/2015/02/prweb12506359.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2015 Category: Pharmaceuticals Source Type: news

Department of Defense Doubles Cancer Research Funding in 2015
Doctors and researchers seeking a cure for mesothelioma will soon be able to tap into millions of dollars set aside by the U.S. Department of Defense for cancer research. The Office of Congressionally Directed Medical Research Programs (CDMRP) invested $50 million in the Peer Reviewed Cancer Research Program (PRCRP) for 2015 — an amount that doubles the money awarded to the program last year. With the additional funding, asbestos-related cancer researchers can extend current studies and launch new ones to improve traditional treatments, introduce emerging therapies or test new cancer drugs. Funding in 2014 was $25 m...
Source: Asbestos and Mesothelioma News - February 5, 2015 Category: Environmental Health Authors: Walter Pacheco Tags: Research & Clinical Trials Source Type: news

FASEB Science Research Conference: Hematologic Malignancies
(Federation of American Societies for Experimental Biology) This FASEB Science Research Conference has a long pedigree as one of the premier meetings for fundamental and translational research in the hematologic malignancies including acute and chronic leukemia, the myeloproliferative neoplasms, myelodysplastic syndromes, myeloma and lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2015 Category: Global & Universal Source Type: news

Galena completes patient enrolment in Phase II GALE-401 trial
Galena Biopharma has completed patient enrolment in the GALE-401, or Anagrelide Controlled Release, Phase II clinical trial to treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET… (Source: Drug Development Technology)
Source: Drug Development Technology - November 20, 2014 Category: Pharmaceuticals Source Type: news

'JAKing' up blood cancers, one cell at a time
(Rockefeller University Press) A solitary cell containing a unique abnormality can result in certain types of blood cancers known as myeloproliferative neoplasms, according to researchers in Switzerland. The results open new opportunities to examine single mutant cells and follow tumor initiation and progression of human MPN cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2014 Category: Global & Universal Source Type: news

Eighty percent of bowel cancers halted with existing medicines
More than 80 percent of bowel cancers could be treated with existing drugs, an international team of scientists say at the conclusion of their study. The study found that medicines called 'JAK inhibitors' halted tumor growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 1, 2014 Category: Science Source Type: news

Eighty percent of bowel cancers halted with existing medicines
(Walter and Eliza Hall Institute) An international team of scientists has shown that more than 80 percent of bowel cancers could be treated with existing drugs.The study found that medicines called 'JAK inhibitors' halted tumor growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2014 Category: Cancer & Oncology Source Type: news

Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders
The protective microenvironment of the hematopoietic stem cell niche, which produces cells of the blood and the immune system, also protects against myeloproliferative neoplasia. Protecting this microenvironment, or niche, has thus emerged as a new route for the treatment of these diseases, for which there is currently no fully effective treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 22, 2014 Category: Science Source Type: news

Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders
(Centro Nacional de Investigaciones Cardiovasculares) The protective microenvironment of the hematopoietic stem cell niche, which produces cells of the blood and the immune system, also protects against myeloproliferative neoplasia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2014 Category: Global & Universal Source Type: news

Erythromelalgia - The Syndrome of Red, Hot Feet - Mayo Clinic video
Erythromelalgia is the name applied to the clinical syndrome of red, hot extremities. Most often, the feet are involved; less often the hands are also involved; rarely, the face (ears especially) may be involved. This short video describes what this syndrome is, what is known about why it happens, how it is diagnosed and managed. Here is a Mayo Clinic video about erythromelalgia:Erythromelalgia is a rare disorder that is characterized by burning pain and warmth and redness of the extremities. There is primary (idiopathic) and secondary erythromelalgia (most commonly associated with myeloproliferative disorders). The name i...
Source: Clinical Cases and Images - May 12, 2014 Category: Journals (General) Tags: Rheumatology Source Type: news

JCI online ahead of print table of contents for May 8, 2014
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, May 8, 2014 in the JCI:Leptin-dependent regulation of reproduction, Female susceptibility to CNS autoimmunity linked to sphingosine-1 phosphate receptor, Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction, Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus, Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm, and more... (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2014 Category: Cancer & Oncology Source Type: news

John Goldman obituary
Pioneer in bone-marrow transplantation for chronic myeloid leukaemia, which has enabled thousands of patients to live normal livesWhen John Goldman began his career in the 1960s, the diagnosis of chronic myeloid leukaemia (CML) carried a grim prognosis and a life expectancy of only three to five years. Today, thousands of patients have been cured or enjoy relatively normal lives because of his seminal contributions. John, who has died aged 75, pioneered bone-marrow transplantation for CML and later championed the drug imatinib that transformed the treatment of the disease.For 23 years from 1988 he was medical director of t...
Source: Guardian Unlimited Science - January 13, 2014 Category: Science Authors: George Q Daley Tags: theguardian.com Obituaries Medical research Cancer Science Source Type: news

Genetic Puzzle Piece for Blood Cancers Found
NEW ORLEANS (MedPage Today) -- Two research groups have filled in another piece of the pathogenetic puzzle of myeloproliferative neoplasms. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 12, 2013 Category: Journals (General) Source Type: news

New Gene Mutation Found in Myeloproliferative NeoplasmsNew Gene Mutation Found in Myeloproliferative Neoplasms
Mutations in a previously unknown gene have been implicated as a primary driver in mechanisms of myeloproliferative neoplasm in patients without JAK and MPL mutations. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Polycythemia Vera, Other MPNs Need Early Treatment, Expert Says
NEW YORK (MedPage Today) -- Therapy for myeloproliferative neoplasms should begin early and low-dose interferon is often the best approach, a leading expert said at a recent symposium here. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 27, 2013 Category: Journals (General) Source Type: news

Genetics Home Reference: 8p11 myeloproliferative syndrome
(Source: NLM General Announcements)
Source: NLM General Announcements - July 9, 2013 Category: Databases & Libraries Source Type: news

Direct Healthcare Professional Communication on association between anagrelide (Xagrid®) therapy and cardiovascular risk
Source: MHRA Area: News Shire has issued a Direct Healthcare Professional Communication regarding the association of anagrelide hydrochloride (Xagrid®) with cardiovascular risk in patients with essential thrombocythaemia (ET), regardless of the patient's medical history, and to remind healthcare professionals that it is indicated as a second-line therapy in at risk patients.   Shire recently conducted a review of all cardiac adverse events in patients
Source: NeLM - News - February 4, 2013 Category: Drugs & Pharmacology Source Type: news

Methods for Detecting Mutations in the Human JAK2 Gene
Mutations in the JAK2 gene are prevalent in the human myeloid malignancies, being present in virtually all cases of polycythemia vera, and a significant proportion of patients with other myeloproliferative disorders. Various methods for the detection of acquired mutations in this gene are available depending on the need for sensitivity, quantification, or the ability to detect many different mutations. We summarize the various methods published and discuss their relative merits for each application. Two commonly used methods, quantitative real-time PCR (QPCR) for the detection of the JAK2 V617F mutation and high resolution...
Source: Springer protocols feed by Cell Biology - January 11, 2013 Category: Cytology Source Type: news

In Vitro JAK Kinase Activity and Inhibition Assays
The discovery that a range of myeloproliferative diseases and leukemias are associated with Janus Kinase (JAK) mutations has highlighted the importance of JAK/STAT signalling in disease and sparked a renewed interest in developing JAK inhibitors. In vitro kinase assays are the most direct and quantitative method to assess mutant forms of JAK for altered enzymatic properties as well as verifying and quantifying the affinity and efficacy of potential inhibitors. Here, we describe protocols for heterologous expression and purification of JAK kinases from insect cells, assays to determine the activity of these purified kinases...
Source: Springer protocols feed by Cell Biology - January 11, 2013 Category: Cytology Source Type: news